Beijing Tiantan Biological Products Management
Management criteria checks 3/4
Beijing Tiantan Biological Products' CEO is Yanlin He, appointed in Dec 2023, has a tenure of 1.42 years. directly owns 0.001% of the company’s shares, worth CN¥420.32K. The average tenure of the management team and the board of directors is 1.5 years and 4 years respectively.
Key information
Yanlin He
Chief executive officer
CN¥862.3k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.001% |
| Management average tenure | 1.5yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
CEO
Yanlin He (56 yo)
Mr. Yanlin He serves as Deputy General Manager and Director of Beijing Tiantan Biological Products Co., Ltd.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 4.9yrs | no data | 0.0024% CN¥ 897.4k | |
| Deputy GM & Director | 1.4yrs | CN¥862.30k | 0.0011% CN¥ 420.3k | |
| General Counsel & Chief Compliance Officer | 1.1yrs | CN¥930.00k | 0.0012% CN¥ 458.2k | |
| Deputy GM & Director | 4.9yrs | CN¥812.60k | 0.0017% CN¥ 658.9k | |
| Chief Financial Officer | 1.5yrs | no data | no data |
Experienced Management: 600161's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 4.9yrs | no data | 0.0024% CN¥ 897.4k | |
| Deputy GM & Director | 1.4yrs | CN¥862.30k | 0.0011% CN¥ 420.3k | |
| Deputy GM & Director | 3yrs | CN¥812.60k | 0.0017% CN¥ 658.9k | |
| Independent Director | 4.9yrs | CN¥240.00k | no data | |
| Independent Director | 4.9yrs | CN¥240.00k | no data | |
| Employee Supervisor | 4.9yrs | no data | 0.00056% CN¥ 212.1k | |
| Supervisor | 3yrs | no data | no data | |
| Chairman of the Supervisory Board | 2yrs | no data | no data |
Experienced Board: 600161's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 18:47 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beijing Tiantan Biological Products Co., Ltd. is covered by 21 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Changming He | BOCI Research Ltd. |
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Sophia Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |